Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Proteros Elects New Supervisory Board Member

Published: Thursday, February 20, 2014
Last Updated: Thursday, February 20, 2014
Bookmark and Share
Shareholders confirmed the appointment of Prof. Eric-Paul Pâques as a new member of the Supervisory Board.

Prof. Pâques is presently CEO and Chairman of the Corporate Executive Board of Grünenthal, an international research-based pharmaceutical company headquartered in Aachen, Germany. Prior to his more than 20 years at Grünenthal, he worked as the Head of Research at Behringwerke AG, in Germany. Prof. Pâques received a doctorate in Chemistry from the Université Catholique de Louvain.

“We are delighted to have Eric-Paul joining our board” commented Dave Lemus, Chairman of the Supervisory Board of Proteros. “His extensive experience in the pharmaceutical industry will prove invaluable to Proteros as the company accelerates its transition to the next phase of its development.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Proteros and Eisai Achieve Target in Lead Discovery Project
Companies delivering kinetically optimized lead compounds.
Tuesday, May 07, 2013
Proteros and Eisai Co., Ltd Enter into Integrated Lead Discovery Collaboration
Companies partner to identify small molecule inhibitors.
Monday, April 16, 2012
Proteros and SUPERGEN Enter Into an Integrated Lead Discovery Agreement
Under the agreement, Proteros will collaborate on the discovery of small molecule lead compounds against a specific target of interest.
Friday, February 04, 2011
Proteros Enters into a Research Agreement for Structure Based Lead Generation
Proteros will perform research to discover small molecule lead compounds against a specific target for delivery to J&JPRD.
Tuesday, September 28, 2010
Proteros Announces Expansion of Commercial Organization in USA and Japan
Company has confirmed its annual financial statement for 2009, which showed a growth rate, in revenues, in excess of 30% while maintaining profitability.
Friday, August 13, 2010
Proteros Biostructures Announces Collaboration with UCB
Proteros to leverage its expertise in gene-to-structure projects and technologies to solve the three dimensional structure of an undisclosed target.
Monday, March 09, 2009
Proteros Biostructures Raises 5.2 Million Euros for Business Expansion
The capital provided by BayBG will be utilized for increasing service capacity and expanding the fragment screening and protein production areas.
Thursday, August 23, 2007
Scientific News
Spero Therapeutics Announces $30 Million Series B Preferred Financing
Company has announced financing of $30 million to support development of novel therapies to treat gram-negative bacterial infections.
Keeping Tumor Growth at Bay
Engineers at Washington University in St. Louis found a way to keep a cancerous tumor from growing by using nanoparticles of the main ingredient in common antacid tablets.
Future of Medicine Could be Found in a Tiny Crystal Ball
A Drexel University materials scientist has discovered a way to grow a crystal ball in a lab. Not the kind that soothsayers use to predict the future, but a microscopic version that could be used to encapsulate medication in a way that would allow it to deliver its curative payload more effectively inside the body.
Improving Delivery of Poorly Soluble Drugs Using Nanoparticles
A technology that could forever change the delivery of drugs is undergoing evaluation by the Technology Evaluation Consortium™ (TEC). Developed by researchers at Northeastern University, the technology is capable of creating nanoparticle structures that could deliver drugs into the bloodstream orally – despite the fact that they are normally poorly soluble.
Faster Drug Discovery?
Startup develops more cost-effective test for assessing how cells respond to chemicals.
New Mechanism of Antitumor Action Identified
A team of UAB researchers and collaborators from the Catalan biotech company Ability Pharmaceuticals (UAB Research Park), have described a new mechanism of anti-tumour action, identified during the study and development of the new drug ABTL0812.
Nanoparticles Deliver Tumor Suppressors to Damaged Livers
UT Southwestern Medical Center chemists have successfully used synthetic nanoparticles to deliver tumor-suppressing therapies to diseased livers with cancer, an important hurdle scientists have been struggling to conquer.
Experimental Combination Surprises with Anti-HIV Effectiveness
A compound developed to protect the nervous system from HIV surprised researchers by augmenting the effectiveness of an investigational antiretroviral drug beyond anything expected.
A New Type of Anticancer Agent
Success in the development of a ?-tubulin specific inhibitor.
Nanoparticles Proven Effective Against Antibiotic-Resistant “Superbugs”
In the ever-escalating evolutionary battle with drug-resistant bacteria, humans may soon have a leg up thanks to adaptive, light-activated nanotherapy developed by researchers at the University of Colorado Boulder.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!